Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 3,305 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

NCT03834883
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 1 Interventional

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04045795
View directory record Official record
Conditions
Multiple Myeloma
Interventions
isatuximab SAR650984 IV, pomalidomide, dexamethasone, isatuximab SAR650984 SC, Investigational injector device
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Gilbert, Arizona • Duarte, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

Treatment for Completers of the Study B7A-MC-MBCM

NCT00266695
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ruboxistaurin
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

NCT00995930
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

NCT01457430
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 4 Interventional

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637
View directory record Official record
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 1 Interventional

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

NCT00761722
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Leukemia, Myelomonocytic, Chronic
Interventions
azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
11
States / cities
Greenbrae, California • Ocoee, Florida • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 17, 2026, 9:02 AM EDT
Completed No phase listed Observational

Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia

NCT00004353
View directory record Official record
Conditions
Mitochondrial Myopathy, MELAS Syndrome, Lactic Acidosis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1978
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2008 · Synced Oct 17, 2026, 9:02 AM EDT
Not yet recruiting Not applicable Interventional

Optimal Dosing of High-Intensity Locomotor Training for Step Attainment and Locomotor Outcomes in Stroke Patients Undergoing Acute Inpatient Rehabilitation

NCT06637839
View directory record Official record
Conditions
Stroke
Interventions
Moderate-Intensity Locomotor Training Program, High-Intensity Locomotor Training Program, High-Step Count Locomotor Training Program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

NCT02427802
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Infection
Interventions
Gentamicin collagen sponge, Placebo
Drug · Other
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 85 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Mesa, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

NCT00097695
View directory record Official record
Conditions
Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Not applicable Interventional Results available

Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices

NCT02407457
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
AFX EVAR AAA Graft System, FDA Approved EVAR AAA Graft Systems
Device
Lead sponsor
Endologix
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
56
States / cities
Florence, Alabama • Huntsville, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 17, 2026, 9:02 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT04045028
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
Interventions
Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

NCT00396331
View directory record Official record
Conditions
Autologous Stem Cell Transplantation
Interventions
G-CSF plus plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 17, 2026, 9:02 AM EDT
Active, not recruiting No phase listed Observational

Geko™ Cross Therapy Registry - Wound

NCT05007301
View directory record Official record
Conditions
Wound, Venous Leg Ulcer, Diabetic Foot Ulcer, Arterial Leg Ulcer
Interventions
geko device
Device
Lead sponsor
Firstkind Ltd
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers

NCT04817228
View directory record Official record
Conditions
Venous Leg Ulcer, Diabetic Foot Ulcer
Interventions
EscharEx (EX-02 formulation)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tamarac, Florida • Las Vegas, Nevada • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 3 Interventional

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

NCT03614234
View directory record Official record
Conditions
Fabry Disease
Interventions
pegunigalsidase alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 9:02 AM EDT
Active, not recruiting Not applicable Interventional

The JenaValve ALIGN-AR Pivotal Trial

NCT04415047
View directory record Official record
Conditions
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
Interventions
JenaValve Trilogy Heart Valve System
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 17, 2026, 9:02 AM EDT
Terminated Phase 1 Interventional Results available

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT02675452
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
Interventions
AMG 176, Azacitidine, Itraconazole
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Not applicable Interventional

Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers

NCT02870816
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Tissue Engineered Skin Substitute, Offloading, Amnionic Membrane Graft
Procedure · Device
Lead sponsor
Professional Education and Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Martinsville, Virginia • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 17, 2026, 9:02 AM EDT
Terminated No phase listed Observational

CorPath GRX STEMI Study

NCT04459299
View directory record Official record
Conditions
STEMI - ST Elevation Myocardial Infarction, CAD
Interventions
Robotic-PCI (CorPath GRX System)
Device
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Not applicable Interventional

Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma

NCT04248244
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Palliative Care, FACT-MM questionnaire, HADS questionnaire
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Not applicable Interventional Results available

Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries

NCT02522884
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Tack Endovascular System
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Yuma, Arizona • Little Rock, Arkansas • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 17, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

NCT01386658
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
icatibant
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Shreveport, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 9:02 AM EDT